Unlike humans, zebrafish can completely regenerate their hearts after injury. They owe this ability to the interaction between their nervous and immune systems, as researchers led by Suphansa Sawamiphak from the Max Delbrück Center now report in the…
Blood cancer is often driven by mutations in stem cells, which are key target cells in the search for innovative early-stage therapies. Dr. Simon Haas, head of a lab within the joint research focus of the Berlin Institute of Health at Charité (BIH),…
World Health Summit – Catalyst and think tank for global health
Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma).
Swapping just a single amino acid can play a decisive role in transforming healthy B cells into cancer cells. An international team led by ECRC researcher Stephan Mathas describes in “Nature Communications” how a point mutation in the transcription…
Synthetic biology startup Cambrium announces €8 Million in Seed financing, led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital. Seed financing will drive commercial growth for Cambrium’s first product, NovaColl™, and…
To make stem cells differentiate, scientists “feed” them with growth factors and embed them in a nutrient solution. There, the cells bunch together in tiny clumps and begin functioning and interacting as if they were in a real tissue. Previously, it…
Organoids help researchers understand biological processes in health and in disease. It is, however, difficult to influence the way in which they organize themselves into complex tissues. Now a group led by Nikolaus Rajewsky has found a new way to do…
Charité – Universitätsmedizin Berlin has placed 27th out of 1,059 universities scored in the Times Higher Education (THE) World University Subject Rankings for 2024 in the “Clinical and Health” category. The result means Charité has built on its…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze)signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. 177Lu). Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and…
